What is Rivia?
Rivia operates at the intersection of artificial intelligence and clinical research, providing a sophisticated platform designed to unify disparate data streams. In an industry often hampered by data silos and manual processing, Rivia enables biotech and pharmaceutical teams to streamline operations and enhance data integrity. By leveraging advanced analytics, the company empowers researchers to make faster, data-driven decisions, effectively reducing the time-to-market for critical medical therapies. Its market position is defined by its ability to bridge the gap between raw clinical data and actionable insights, a necessity for modern enterprise-level drug development.
How much funding has Rivia raised?
Rivia has raised a total of $18.8M across 2 funding rounds:
Seed
$3.5M
Series A
$15.2M
Seed (2024): $3.5M with participation from Speedinvest
Series A (2026): $15.2M led by Nina Capital, Amino Collective, Speedinvest, and Earlybird
Key Investors in Rivia
Speedinvest
Speedinvest is a venture capital fund with over 1B Euro allocated for investing in pre-Seed, Seed, and early-stage tech startups across Europe, focusing on sectors including Health Bio and SaaS Infra.
Nina Capital
Nina Capital is a specialized venture capital firm focused on investing in health technology companies at the pre-seed and seed stages, aiming to transform healthcare through information technology.
Amino Collective
Amino Collective focuses on investing in health and bio sectors, supporting early-stage ventures with a European focus that aim to scale globally.
What's next for Rivia?
With this major enterprise-level funding, Rivia is well-positioned to accelerate its product development roadmap and expand its footprint within the European and international biotech markets. The strategic focus will likely shift toward scaling its engineering teams and enhancing the predictive capabilities of its AI engine to handle increasingly complex trial datasets. As the company matures, the focus will remain on deepening its integration with existing pharmaceutical R&D ecosystems, ensuring that its platform becomes an indispensable tool for global clinical trial management. The backing from prominent venture capital firms provides not only the necessary liquidity but also the strategic guidance required to navigate the highly regulated healthtech landscape.
See full Rivia company page
